Indication

HER2-positive Bladder Cancer

2 clinical trials

1 product

Clinical trial

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Status: Completed, Estimated PCD: 2022-08-11

Product

Clinical trial

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Status: Completed, Estimated PCD: 2023-12-01